GT
AMRI

Glenmede Trust’s Albany Molecular Research Inc AMRI Stock Holding History

Glenmede Trust’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-163
Closed -$2K – 2946
2017
Q2 		$2K Hold
163
– – ﹤0.01% 2546
2017
Q1 		$2K Buy
163
+146
+859% +$2.39K ﹤0.01% 2546
2016
Q4 		$0 Hold
17
– – ﹤0.01% 2718
2016
Q3 		$0 Sell
17
-80
-82% -$1.19K ﹤0.01% 2748
2016
Q2 		$1K Sell
97
-648
-87% -$9.45K ﹤0.01% 2513
2016
Q1 		$10K Buy
745
+355
+91% +$5.56K ﹤0.01% 2059
2015
Q4 		$6K Buy
390
+53
+16% +$1.01K ﹤0.01% 2232
2015
Q3 		$5K Buy
337
+189
+128% +$3.85K ﹤0.01% 2329
2015
Q2 		$2K Buy
+148
New +$2.86K ﹤0.01% 2492
2014
Q4 		– Sell
-228
Closed -$5K – 2662
2014
Q3 		$5K Buy
+228
New +$4.67K ﹤0.01% 2250

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Glenmede Trust's AMRI Position: Q3 2017 in Review

Glenmede Trust sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 163 shares — an estimated $2K sold.

Glenmede Trust first reported a position in AMRI in Q3 2014 and held it in 10 quarters. The position peaked at $10K in Q1 2016. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Glenmede Trust reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Glenmede Trust sold 163 Albany Molecular Research Inc shares in Q3 2017, an estimated $2K.
  • Glenmede Trust first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 10 quarters.
  • Glenmede Trust's Albany Molecular Research Inc position peaked at $10K in Q1 2016.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.